08/26/2026
๐ช๐ต๐ฎ๐ ๐ถ๐ณ ๐๐ผ๐บ๐ฒ ๐ผ๐ณ ๐๐ต๐ฒ ๐ฑ๐ผ๐ด๐ ๐๐ต๐ฎ๐ ๐ฎ๐ฟ๐ฒ ๐ต๐ฎ๐ฟ๐ฑ๐ฒ๐๐ ๐๐ผ ๐ฐ๐ฎ๐๐ฐ๐ต ๐ณ๐ผ๐ฟ ๐๐ฎ๐ฐ๐ฐ๐ถ๐ป๐ฎ๐๐ถ๐ผ๐ป ๐ฐ๐ผ๐๐น๐ฑ ๐ฏ๐ฒ ๐ฟ๐ฒ๐ฎ๐ฐ๐ต๐ฒ๐ฑ ๐๐ถ๐๐ต ๐ฎ ๐๐ฎ๐ฐ๐ฐ๐ถ๐ป๐ฒ ๐ฏ๐ฎ๐ถ๐ ๐ถ๐ป๐๐๐ฒ๐ฎ๐ฑ?
A new 2026 analysis evaluated serological data from experimental and field studies investigating the third-generation oral rabies vaccine strain SPBN GASGAS in dogs, including free-roaming populations from multiple countries.
The findings were encouraging:
โข The antibody response was measurable and remained detectable over extended follow-up periods.
โข Bait matrix, sachet type, and vaccine titre did not significantly affect the measured antibody response.
โข At approximately one month after vaccination, antibody levels measured by ELISA were not significantly different between field and experimental dogs receiving the same egg-flavored bait.
โข In the pooled field-study data, 83% of samples met the studyโs ELISA seropositivity threshold after oral vaccination.
Onset of protective immunity is expected from 15 days after vaccination. Serological studies demonstrated persistence of antibodies at levels considered indicative of protective immunity for at least 30 months
Importantly, this study measured rabies virusโbinding antibodies (RVBA) using a blocking ELISA. That is not the same as directly measuring rabies virusโneutralizing antibodies, and the authors caution that ELISA results are an approximation of protection rather than a direct measure of whether an individual dog is protected.
Still, the results add to the evidence that oral rabies vaccination could be a valuable complementary strategy for reaching free-roaming dogs that are difficult to access with conventional injectable vaccination campaigns.
Vos A, et al. Veterinary Immunology and Immunopathology. 2026;299:111193.